Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples

Biomarkers reliably predicting progression to multiple myeloma (MM) are lacking. Myeloma risk has been associated with low blood levels of monocyte chemotactic protein-3 (MCP-3), macrophage inflammatory protein-1 alpha (MIP-1α), vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (...

Descripción completa

Detalles Bibliográficos
Autores principales: Späth, Florentin, Wibom, Carl, Krop, Esmeralda J. M., Santamaria, Antonio Izarra, Johansson, Ann-Sofie, Bergdahl, Ingvar A., Hultdin, Johan, Vermeulen, Roel, Melin, Beatrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959165/
https://www.ncbi.nlm.nih.gov/pubmed/30948485
http://dx.doi.org/10.3324/haematol.2019.216895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959165/
https://www.ncbi.nlm.nih.gov/pubmed/30948485
http://dx.doi.org/10.3324/haematol.2019.216895

Ejemplares similares